Celyad Oncpology change in strategy and prorities.
Celyad oncology announced a strategic shift in to prioritize discovery research in areas of expertise where it can leverage the differentiated nature of its platforms.
The Company has implemented a differentiated and innovative strategy, which it believes has the potential to tackle the major current limitations of CAR T-cell therapies. This strategy includes a multiplexing approach of the short hairpin RNA (shRNA) platform, a dual CAR development of a next-generation NKG2D-based CAR, and the development of B7-H6-targeting immunotherapies.
Related news and insights
The Board of Directors of Jounce Therapeutics, Inc. a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, confirmed that Concentra Biosciences, LLC , of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal to acquire 100% of the equity of Jounce. According to the Schedule 13D filed with the U.S. Securities and Exchange Commission (“SEC”) disclosing the Proposal, Tang Capital is currently approximately a 10.2% shareholder of Jounce.